Miguel Lopez-Lazaro
Miguel Lopez-Lazaro
Department of Pharmacology, University of Seville, Spain
Verified email at us.es
Title
Cited by
Cited by
Year
A review on the dietary flavonoid kaempferol
J M Calderon-Montano, E Burgos-Morón, C Pérez-Guerrero, ...
Mini reviews in medicinal chemistry 11 (4), 298-344, 2011
8282011
Distribution and biological activities of the flavonoid luteolin
M López-Lázaro
Mini reviews in medicinal chemistry 9 (1), 31-59, 2009
8032009
Dual role of hydrogen peroxide in cancer: possible relevance to cancer chemoprevention and therapy
M Lopez-Lázaro
Cancer letters 252 (1), 1-8, 2007
4962007
Anticancer and carcinogenic properties of curcumin: considerations for its clinical development as a cancer chemopreventive and chemotherapeutic agent
M López‐Lázaro
Molecular nutrition & food research 52 (S1), S103-S127, 2008
4372008
Flavonoids as anticancer agents: structure-activity relationship study
M Lopez-Lazaro
Current Medicinal Chemistry-Anti-Cancer Agents 2 (6), 691-714, 2002
3142002
The warburg effect: why and how do cancer cells activate glycolysis in the presence of oxygen?
M López-Lázaro
Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal …, 2008
3112008
The dark side of curcumin
E Burgos‐Morón, JM Calderón‐Montańo, J Salvador, A Robles, ...
International journal of cancer 126 (7), 1771-1775, 2010
2592010
Digitoxin inhibits the growth of cancer cell lines at concentrations commonly found in cardiac patients
M López-Lázaro, N Pastor, SS Azrak, MJ Ayuso, CA Austin, F Cortés
Journal of Natural Products 68 (11), 1642-1645, 2005
1992005
Cytotoxic effect of Plantago spp. on cancer cell lines
M Galvez, C Martın-Cordero, M Lopez-Lazaro, F Cortes, MJ Ayuso
Journal of ethnopharmacology 88 (2-3), 125-130, 2003
1862003
Digitoxin as an anticancer agent with selectivity for cancer cells: possible mechanisms involved
M López-Lázaro
Expert opinion on therapeutic targets 11 (8), 1043-1053, 2007
1382007
A new view of carcinogenesis and an alternative approach to cancer therapy
M López-Lázaro
Molecular medicine 16 (3), 144-153, 2010
1342010
Pro-oxidant natural products as anticancer agents
C Martin-Cordero, A Jose Leon-Gonzalez, J Manuel Calderon-Montano, ...
Current drug targets 13 (8), 1006-1028, 2012
1222012
Curcumin as a DNA topoisomerase II poison
C Martín-Cordero, M López-Lázaro, M Gálvez, M Jesús Ayuso
Journal of enzyme inhibition and medicinal chemistry 18 (6), 505-509, 2003
1172003
HIF‐1: hypoxia‐inducible factor or dysoxia‐inducible factor?
M López‐Lázaro
The FASEB journal 20 (7), 828-832, 2006
982006
The dietary flavonoids myricetin and fisetin act as dual inhibitors of DNA topoisomerases I and II in cells
M López-Lázaro, E Willmore, CA Austin
Mutation Research/Genetic Toxicology and Environmental Mutagenesis 696 (1 …, 2010
932010
Evaluating the cancer therapeutic potential of cardiac glycosides
JM Calderón-Montańo, E Burgos-Morón, ML Orta, D Maldonado-Navas, ...
BioMed research international 2014, 2014
852014
Cells lacking DNA topoisomerase IIβ are resistant to genistein
M López-Lázaro, E Willmore, CA Austin
Journal of natural products 70 (5), 763-767, 2007
752007
Curcumin induces high levels of topoisomerase I− and II− DNA complexes in K562 leukemia cells
M López-Lázaro, E Willmore, A Jobson, KL Gilroy, H Curtis, K Padget, ...
Journal of natural products 70 (12), 1884-1888, 2007
732007
Assessment of genotoxic damage by the comet assay in white storks (Ciconia ciconia) after the Donana ecological disaster
N Pastor, M López-Lázaro, JL Tella, R Baos, F Hiraldo, F Cortés
Mutagenesis 16 (3), 219-223, 2001
672001
The stem cell division theory of cancer
M López-Lázaro
Critical Reviews in Oncology / Hematology 123 (3), 95-113, 2018
652018
The system can't perform the operation now. Try again later.
Articles 1–20